重大公告
Announcements
OBI Filed the Application of Phase III Human Clinical Study for the Active Cancer Immunotherapy OBI-822, Adagloxad Simolenin, to the Health Authority of Peru
1. Date of occurrence of the event: Apr 20, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …
Announcements
OBI’s application to initiate the Phase III clinical study of the active cancer immunotherapy OBI-822 (Adagloxad Simolenin) has been denied by the Ministry of Health, Argentina
1. Date of occurrence of the event: Apr 7, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …
Announcements
OBI filed the application to EMA for Phase III human clinical study of the active cancer immunotherapy OBI-822, Adagloxad Simolenin, in Spain, German, and Poland
1. Date of occurrence of the event: Mar 17, 2021 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” …
Announcements
The Board of Directors resolved to hold 2021 Annual General Meeting
1. Date of the board of directors resolution: Mar 12, 2021 2. Date for convening the shareholders’ meeting: Jun 21, 2021 3. Location for convening …
Announcements
Announcement of not Distributing Dividends in 2020
1. Date of the board of directors resolution: Mar 12, 2021 2. Year or quarter which dividends belong to: Year of 2020 3. Period which …